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Urinary albumin-creatinine ratio is a marker of diabetic nephropathy and microvascular damage. 
Metabolic-related traits are observationally associated with ACR but their causal role is 
uncertain.  Here, we confirmed ACR as a marker of microvascular damage and tested whether 
metabolic-related traits have causal relationships with ACR. 
The association between ACR and microvascular function (responses to acetylcholine and 
sodium nitroprusside) were tested in the SUMMIT study. Two sample Mendelian randomization 
(MR) was used to infer the causal effects of eleven metabolic risk factors, including glycemic, 
lipid and adiposity traits on ACR. MR was performed in up to 440,000 UK Biobank and 54,451 
CKDGen participants. 
ACR was robustly associated with microvascular function measures in SUMMIT. Using MR we 
inferred that higher triglyceride and LDL-cholesterol levels caused elevated ACR. A one 
standard deviation (SD) higher triglyceride and LDL-C level caused a 0.062 [95%CI: 0.040, 
0.083] and a 0.026 [95%CI: 0.008, 0.044] SD higher ACR respectively. There was evidence that 
higher body fat and visceral body fat distribution caused elevated ACR, whilst a metabolically 
“favourable adiposity” phenotype lowered ACR.   
ACR is a valid marker for microvascular function. MR suggested that 7 traits have causal effects 





The urinary albumin-creatinine ratio, a marker of diabetic nephropathy, is used as a proxy for 
damage to the systemic microcirculation (1) and predicts first myocardial infarction and mortality 
in those with diabetes, post stroke and the general population (2-4). There is evidence linking 
metabolic-related traits, including adiposity, dyslipidemia and insulin resistance with elevated 
ACR levels and microvascular damage (5; 6). It is well accepted that tight glucose control in 
patients with type 2 diabetes (T2D) reduces the risk of microvascular retinal complications (7; 8) 
and there is evidence that adiposity per se is associated with increased ACR. For example, 
population studies suggest that microalbuminuria is associated with central adiposity (9) and 
results from The Framingham Heart Study show that visceral but not subcutaneous fat is 
associated with increased albuminuria (10). Not all evidence linking metabolic-related traits 
come from randomized control trials and, in absence of these, the next best evidence of 
causality comes from genetic studies using a technique known as Mendelian randomization 
(MR, Figure 1). 
In MR, genetic variants that are strongly associated with the risk factor of interest are used to 
test its causal effect on an outcome (11). The MR approach exploits the natural experiment of 
genetic variants being randomly assigned at conception, which means they are less likely to be 
associated with confounding factors and should not suffer from reverse causality (12). MR 
studies investigating the role of metabolic traits in increasing microvascular damage, including 
ACR, infer causal relationships for higher blood pressure (13) but not for lipids (14), but the 
latter study was small, limited in power and focused only on people with diabetes. 
Here, we utilised data from 743 participants in the SUrrogate markers for Micro- and Macro-
vascular hard endpoints for Innovative diabetes Tools (15) study to first confirm that ACR is a 
suitable proxy for early systemic microvascular damage, by testing its association with two 
validated measures of microvascular function – skin microvascular response to iontophoresis of 
vasodilators acetylcholine (endothelial dependent)  and sodium nitroprusside (endothelial 
independent). Second, we tested the observational associations between ACR and 9 metabolic 
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risk factors in 438,075 participants in the UK Biobank. Finally, we used MR to test the effects of 
11 metabolic risk factors on microvascular function using ACR as a proxy in the UK Biobank 




The UK Biobank study recruited over 500,000 individuals aged between 37 and 73 years 
between 2006 and 2010. The study collected detailed information from all participants, via 
questionnaires, interviews and measurements (16). Here we used 438,075 individuals of White 
European ancestry (defined through principal component-based analyses (17) with ACR 
available.  We also defined a subset of 368,754 unrelated individuals of European ancestry. 
Related individuals were defined using a KING Kinship and an optimal list of unrelated 
individuals was generated to allow maximum numbers of individuals to be included. Ancestral 
principal components were then generated within these identified individuals for use in 
subsequent analyses. 
SUMMIT 
Data for observational association and functional measures of microvascular function were 
collected in 743 individuals from two centres (Exeter and Dundee) participating in the vascular 
imaging cohort of the SUMMIT study. SUMMIT is a multicentre study aiming at identifying 
markers that predict the risks of developing diabetes related chronic micro- and macro-vascular 
complications (15; 18). 
Validation of ACR as a proxy for microvascular function 
In SUMMIT, skin microvascular function in the forearm is measured using laser Doppler 
fluximetry. A laser Doppler imager (LDI, Moor Instruments MODEL LDI2) was used to measure 
perfusion before and after iontophoresis of endothelium dependent (acetylcholine , ACH) and 
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endothelium independent (sodium nitroprusside) vasodilatory stimuli. The full protocol of the 
techniques used are detailed elsewhere (18). 
ACR was measured in SUMMIT from random spot urine collection (Exeter Pathology Services, 
Royal Devon and Exeter NHS Foundation Trust, and Dundee Pathology Services, Ninewells 
NHS trust), in accordance with the UK national quality assessment scheme. Analysis of albumin 
concentration was performed using immunoturbidimetric method a detection limit of 3.0 mg/L 
(Cobas system, Roche), creatinine was measured using the Jaffe methods. In order to maintain 
a consistent approach with UK Biobank analysis, values below detection limit were set at 2.9 
mg/L prior to the calculation of the ratio. The ACR variable was inverse normalised prior to 
analysis. 
The relationship between the gold standard microvascular functional measures and ACR was 
explored using linear regression models, with age and sex included as covariates.  
Exposure and outcome measures in UK Biobank 
We selected 11 metabolic markers which have previously been associated with ACR and have 
strong genetic instruments available in the form of multiple variants (Supplementary table 2) 
identified in large genome wide association studies (GWAS). More information on how the 
outcome and exposures were defined in the UK Biobank are explained below. 
OUTCOME: Albumin to creatinine ratio (ACR) 
A continuous measure of ACR was derived using urinary measures of albumin and creatinine. If 
albumin was <6.7 mg/L (the detection level of the assay in UK Biobank, 
http://biobank.ctsu.ox.ac.uk/crystal/docs/urine_assay.pdf) then the albumin was set at 6.7 mg/L 
prior to the calculation of the ratio, an approach consistent with that of previous studies (13; 19). 
Albumin was measured using immuno-turbidimetric analysis method (Randox Bioscience, UK) 
while creatinine was measured using enzymatic analysis method (Beckman Coulter, UK). The 




Nine of the eleven metabolic markers were measured in the UK Biobank.  
Lipids 
Serum concentrations of LDL-Cholesterol (LDL-C, N=417,386) were obtained using an 
Enzymatic Selective Protection analysis method (Beckman Coulter AU5800, Beckman Coulter 
(UK), Ltd), HDL-Cholesterol (HDL-C, N=382,598) using a EnzymeImmuno-inhibition analysis 
method (Beckman Coulter AU5800, Beckman Coulter (UK), Ltd) and triglycerides (TG, 
N=417,825) using Enzymatic analysis method (Beckman Coulter AU5800, Beckman Coulter 
(UK), Ltd). More details on the acquisition of these biomarkers can be found here: 
http://biobank.ndph.ox.ac.uk/showcase/docs/serum_biochemistry.pdf  
Body composition  
We used three measures of body composition: body mass index (BMI), waist hip ratio (WHR) 
adjusted for BMI and, using genetics, a measure of higher body fat percentage but lower 
metabolic disease risk, termed favourable adiposity. BMI was calculated for all participants from 
measured weight and height ((kg)/height (m)2) and was available for 436,631 individuals with 
ACR and genetic data available. WHR was calculated from measured waist and hip 
circumference measures and adjusted for BMI, this was available in 436,530 individuals.  Body 
fat percentage was calculated from bioelectrical impedance data collected using Tanita 
BC418MA body composition analyser and was available in 430,546 individuals. 
Blood pressure 
Systolic blood pressure (SBP, N=437,121) and diastolic blood pressure (DBP, N=436,394) were 
measured. The blood pressure readings were obtained from averaging two readings obtained in 
a seated position 5 minutes apart using an automated blood pressure device (Omron 705 IT, 
Omron Healthcare Europe B.V. Hoofddorp, The Netherlands). In participants where only one 
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valid blood pressure was available this was utilised. Blood pressure medication use was 
accounted for by adding 10 and 15 to diastolic and systolic measures respectively. 
Type 2 diabetes (T2D) 
Type 2 diabetes cases were defined through self-report of diabetes using the baseline 
questionnaire. Cases were participants diagnosed at >35 years of age, and without reporting of 
insulin use within the first year of diagnosis (20). This resulted in 13,799 cases and 415,908 
controls (Table 1). 
Metabolic predictors not available in the UK Biobank 
Two measures of glycemic control were not measured in the UK Biobank at the time of study: 
fasting glucose (FG) and fasting insulin (FI). 
 
For all continuous measurements in UK Biobank values more than 4.56SD away from the mean 
were excluded. These variables when then inverse normalised prior to analysis.  
 
The observational associations between the measured exposures and ACR were tested in UK 
Biobank using linear regression models, adjusted for age, sex and assessment centre.  
 
Genetic variants 
For Mendelian randomization (MR) independent genetic variants were selected from the UK 
Biobank imputation dataset. Variants were excluded if imputation quality (INFO) was <0.3 or the 
minor allele frequency (MAF) was <0.1%. 
The genetic variants for the exposure traits were selected based on published GWAS studies. 
Genetic variants were selected and extracted for the 11 metabolic markers including lipid levels 
(triglycerides, HDL-C and LDL-C), BMI, favourable adiposity (genetic variants associated with 
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higher body fat percentage but lower risk of metabolic disease (e.g. type 2 diabetes, coronary 
heart disease)), WHR (adjusted for BMI), systolic and diastolic blood pressure, type 2 diabetes, 
fasting glucose and fasting insulin (Supplementary table 2). Four variants were identified that 
were previously identified to associate with ACR at genome wide significance: rs1047891 (HDL 
variant), rs4865796 (fasting insulin variant), rs109953111 (DBP variant) and rs2068888 
(triglyceride variant) (21).  
The extracted genetic variants were utilised to create genetic risk scores (GRS) for each 
metabolic trait of interest. The variants were weighted by their effect size (β-coefficient) obtained 
from the primary GWAS, where possible using GWAS that did not include data from the UK 
Biobank (equation 1). The weighted score was then rescaled to reflect the number of trait 
raising alleles (equation 2).  




 (Equation 2) 
 
Mendelian randomization 
We used MR to test for causal relationships between our 11 metabolic risk factors as exposures 
and ACR as an outcome. MR relies on several assumptions as outlined in Figure 1: 
 
● the exposure GRS are robustly associated with the relevant measured exposure 
(Supplementary table 1); 
● the exposure GRS are not associated, independently of their effects on the exposure, 
with confounding factors that bias conventional epidemiological associations. 
● the exposure GRS is only associated with the outcome via its effect on the modifiable 




In this study, we employed several methods of MR: one and two-sample MR. The primary 
analyses utilised data from 438,075 UK Biobank participants with measured ACR. We extracted 
the genetic variants for the 11 known metabolic traits (Supplementary table 2) from the BOLT-
LMM (22) GWAS of ACR, which was adjusted for baseline age, sex, study centre, and 
genotyping array (0=BiLEVE, 1=Axiom UK Biobank interim release, 2=Axiom UK Biobank final 
release). We also extracted association statistics for the same SNPs from the largest GWAS of 
ACR (54,451 participants from CDKGen consortium meta-analysis, Teumer et al. 2016) which 
did not include the UK Biobank.  
Two-sample MR 
Our primary MR approach was to use the inverse variance weighted (IVW) estimator. The IVW 
method involves a weighted regression of the effect sizes of variant-outcome associations 
against the effect sizes of the variant-risk factor associations constraining the intercept to zero. 
The beta coefficient from the weighted regression represents the standard deviation change in 
the ACR per SD change in the outcome variable (with the exception of type 2 diabetes, where 
we present our findings as an SD change in ACR per two-fold higher genetic liability for type 2 
diabetes). Several sensitivity analyses were performed to test whether the MR IVW estimates 
are biased by genetic variants that affect the outcome independently of the exposure of interest 
(i.e. horizontal pleiotropy). These methods were MR-Egger regression (23) and the weighted 
median (WM) estimator (24). MR-Egger is similar to IVW, except that the intercept is 
unconstrained. The intercept in MR-Egger reflects the average pleiotropic effect across genetic 
variants. Hence this method is less susceptible to potentially pleiotropic variants having a 
stronger effect on the outcome compared with their effect on the primary traits. The weighted 
median method is also more resistant to pleiotropy and gives consistent estimates even when 
50% of the variants are invalid. Given these different assumptions, if all methods are broadly 
consistent it strengthens our causal inference. The R code for the various 2-sample methods is 




We performed sensitivity analyses for the four traits where one variant was known to be 
associated with ACR at genome-wide significance. Here, the 2-sample MR was repeated 
excluding that one variant. 
The results from the 2-sample MR in the UK Biobank and the GWAS studies were meta-
analysed using the metan command in Stata.  
 
There is some overlap between the genetic variants for LDL-C, HDL-C and TG. Therefore, as 
well as individually exploring the role of the LDL-C, HDL-C and TG SNPs on the outcomes we 
also ran multivariate models adjusting for the other lipid associations (25). For example, when 
testing the causal role of LDL-C we included the LDL-C-SNP-TG association and the LDL-C-
SNP-HDL association as covariates in our model.  
 
One sample MR 
In an unrelated subset of the data we also performed one-sample MR using the GRS and the 
ivreg2 command in STATA. In these models age, sex, ancestral principal components, 
assessment centre and genotyping platform were included as covariates. In cases where the 
predictor was not measured in the UK Biobank we explored the association of the GRS directly 
with the outcome. As with the two sample MR we performed multivariate analyses for the lipids 
by adjusting models for the other lipid GRS. For example, we performed MR to explore the 
causal role of LDL-C on ACR adjusting our models for all the standard covariates and the HDL-
C and TG GRS.  
 
Data and resource availability 
The UK Biobank resource can be utilised by any bonafide researcher and access to all the 
genetic and phenotypic data utilised in this study are available upon application to the UK 
Biobank (https://www.ukbiobank.ac.uk/). The summary statistics from the CDKGEN are 
12 
 
available: (https://ckdgen.imbi.uni-freiburg.de). SUMMIT data utilised in this study are available 





Characteristics for the 438,075 UK Biobank and 743 SUMMIT participants are presented in 
table 1.  
 
SUMMIT provided evidence that supports the use of ACR as a marker of microvascular 
function 
Results from the SUMMIT study support the use of ACR as a proxy for microvascular function 
with lower microvascular function associated with raised ACR levels. There was a negative 
association between ACR and skin microvascular function for both endothelium dependent 
(ACH) and independent (sodium nitroprusside) function. One SD lower response in endothelium 
dependent microvascular function as measured by skin reactivity to iontophoresis of ACH was 
associated with a 0.155 SD higher ACR (95%CI: 0.078, 0.230, p = 5.8E-05). One SD lower 
response in endothelium independent microvascular function as measured by reactivity to 
sodium nitroprusside was associated with a 0.206 SD higher ACR (95%CI: 0.131, 0.281, p = 
1.1E-07). Taken together these measures demonstrate that lower systemic microvascular 
response measured by skin reactivity to iontophoresis is associated with elevation in urinary 
ACR. 
 
Observational associations for the 11 metabolic traits with ACR 
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Data for observational analyses in UK Biobank were available for 9 of the 11 of exposure traits. 
Observational analyses provided evidence that higher HDL cholesterol, systolic and diastolic 
blood pressure, higher WHR adjusted for BMI and type 2 diabetes were associated with 
elevated ACR (Table 2). Higher LDL cholesterol, triglycerides, BMI and higher body fat 
percentage were associated with lower levels of ACR (Table 2). The inverse association 
between higher LDL cholesterol, triglycerides, BMI and higher body fat with lower ACR was 
unexpected, but maybe due to treatment effects, confounding or survival bias, thus highlighting 
the importance of more robust approaches, like MR. 
 
Mendelian randomization finds a stronger causal role of triglycerides in elevating ACR 
compared to LDL-cholesterol 
MR inferred a causal role of higher TG and LDL-C in elevating ACR, with the effect of TG more 
than twice that of LDL-C. A one-SD higher TG (approximately 86 mg/dl) was associated with a 
0.062 SD [95%CI: 0.040, 0.083] higher ACR (approximately 9.3 mg/mmol, Table 3, Figure 2), 
whilst a one-SD higher LDL-C (approximately 37 mg/dl) was associated with a 0.026 [95%CI: 
0.008, 0.044] SD higher ACR. There was no evidence to infer that higher HDL-C altered ACR. 
The evidence for a causal role of higher TG in elevating ACR was strengthened using 
multivariate MR which adjusted for the association of the TG SNPs with HDL-C and LDL-C. A 
one SD higher TG (adjusted for LDL-C and HDL-C) associated with a 0.094 SD [95%CI: 0.073, 
0.115] higher ACR (Figure 2, Supplementary table 3). In contrast, multivariate analyses 
attenuated the association between LDL-C and ACR, with a one SD higher LDL-C (adjusted for 
TG and HDL-C) associated with a 0.018 SD [95%CI: 0.001, 0.035] higher ACR (Figure 2, 
Supplementary table 3). There was no evidence that higher HDL-C adjusted for LDL-C and TG 
altered ACR. 
Results were generally consistent when the more pleiotropy robust methods were utilised 
(Table 3). The estimates from the two studies (UK Biobank and CKDGen) and the one sample 
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MR in UK Biobank were consistent, strengthening the causal inference between triglycerides 
and ACR (Supplementary table 4, Supplementary figure 1). Findings for HDL and 
triglycerides were the same when variants known to be associated with ACR were excluded.  
 
Mendelian randomization finds causal role of body composition measures in elevating 
ACR 
We next tested three measurements of body size and composition – BMI, waist hip ratio 
(adjusted for BMI) and metabolically “favourable adiposity”.   
The MR analyses suggested that higher WHR caused elevated ACR levels, independently of 
BMI. A one-SD higher WHR adjusted for BMI was associated with a 0.040 SD higher ACR 
([95%CI: 0.020, 0.059]; Table 3, Figure 3).  
MR using the “favourable adiposity” genetic variants (associated with higher body fat 
percentage but lower risk of metabolic diseases (26) showed that metabolically favourable 
higher adiposity was associated with lower ACR (-0.157 [95%CI: -0.256, -0.057], P=0.002; 
Figure 3).  
The MR results for higher BMI were not conclusive, although they were directionally consistent 
with the WHR results.  
Results from alternative MR methods (Table 3) and the study specific results from the UK 
Biobank, CKDGen and the one-sample MR results were generally consistent (Figure 3, 
Supplementary table 4). However, there was weak evidence of heterogeneity for BMI (P = 
0.013, I-squared 83.9%) and favourable adiposity (P = 0.027, I-squared 79.5%).  
 
Meta-analysis of two sample Mendelian randomization infers a causal role of type 2 
diabetes in elevating ACR   
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MR inferred that genetic liability to type 2 diabetes caused elevated ACR levels, with a two-fold 
higher genetic liability to type 2 diabetes associated with 0.013 SD [95%CI: 0.007, 0.018] higher 
ACR levels (Table 3, Figure 4). There was no evidence of a causal relationship between either 
fasting insulin or fasting glucose and ACR.  
Results were consistent when alternative MR methods were used (Table 3, Supplementary 
table 4) and when excluding the fasting insulin SNP that is also associated with ACR. The study 
specific results from the UK Biobank and CKDGen are presented in Supplementary table 4, 
Figure 4. . 
Mendelian randomization confirms causal role of blood pressure in elevating ACR  
MR confirmed previous evidence (13) for the causal relationship between higher blood pressure 
and elevated ACR levels. A 1 mmHg higher systolic and diastolic blood pressure was causally 
associated with a 0.006 [95%CI: 0.004, 0.008] and 0.009 [95%CI: 0.006, 0.012] SD higher ACR 
respectively (Table 3, Figure 5).   
Results were consistent when alternative MR methods were used, although not all reached 
p<0.05 (Table 3). Excluding the one diastolic blood pressure variant that was associated with 
ACR in an independent study did not alter our findings. Study specific results from the UK 
Biobank, CKDGen and the one sample MR methods in the UK Biobank were generally 
consistent (Figure 5, Supplementary table 4), although there was evidence of heterogeneity 
for systolic blood pressure (P = 0.002, I-squared 89.6%).  
 
Discussion 
This study used genetic approaches to infer the causal role of 11 metabolic risk factors on ACR, 
which was considered as a proxy for microvascular dysfunction.  Firstly, we confirmed that ACR 
is a valid proxy for microvascular function, using two gold standard physiological measures of 
microvascular function in the SUMMIT study – skin endothelial dependent and independent 
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microvascular function. We then used genetic variants as unconfounded proxies for the 11 
metabolic risk factors to infer that 7 of the 11 metabolic risk factors cause elevated levels of 
ACR and thus cause microvascular dysfunction.  
Skin microcirculation is an established model to investigate systemic microvascular function 
prior to the clinical manifestation of disease (27). Skin microvascular responses have been 
demonstrated to be reduced in people with type 2 diabetes (18) and associated with coronary 
microvascular function (28). Results presented here support the use of ACR as a proxy for the 
systemic microcirculation and not just for renal microcirculation.   
In keeping with the clinical data, we inferred a causal role of LDL cholesterol and triglycerides in 
raising ACR levels, with multivariate lipid analyses strengthening the triglyceride association and 
attenuating the LDL association. Indeed, the effect of triglycerides on ACR is twice as large as 
the effect of LDL. This contrasts with available evidence for coronary artery disease (CAD) 
where LDL levels have a larger effect on CAD risk than triglycerides.  
Whilst the effect sizes in our results can be seen as small, they represent clinically meaningful 
results. For example, previous studies have demonstrated that small changes in LDL 
cholesterol (e.g. 0.2 magnitude lower LDL in mmol/L) results in a 5 to 10% reduction in the risk 
of CHD (29). The majority of our analyses look at SD changes in ACR per genetically 
instrumented SD change in the predictor. For LDL, this equates to approximately a 0.9 mmol/L 
higher LDL, which in previous studies would equate to a 15 to 40% higher risk of CHD. 
These results are consistent with those from clinical trials of cholesterol lowering medication. 
HMG Co-A reductase inhibitors (statins), predominantly lower LDL cholesterol, and have been 
demonstrated to reduce CAD risk. These drugs, however, only have a small effect on ACR (30), 
and a similarly small impact on other manifestations of microvascular dysfunction such as 
diabetic retinopathy (31). In contrast, PPARα antagonists such as fenofibrate, which act 
predominantly on triglyceride levels, have been shown to have beneficial effect on diabetic 
nephropathy and retinopathy (32). Combined statin-fenofibrate therapies can provide additional 
17 
 
endothelial vascular benefits than statin and fenofibrate alone (33) and, according to the recent 
results of the ACCORD study, it appears to be safe with regards to the risk of myositis or 
rhabdomyolysis when used in combination with a statin (34). Our results suggest that combined 
therapies lowering triglyceride as well as LDL levels could provide compound benefits by 
reducing the atherosclerotic burden, and thus CAD, whilst simultaneously reducing 
microvascular dysfunction which has a greater impact on the quality of life on patients (35). 
We used three complementary measures of body composition to test the role of adiposity and 
body fat distribution on the ACR. These three measures were BMI, waist hip ratio (adjusted for 
BMI) as a measure of central adiposity and “favourable adiposity” as a measure of higher fat 
mass “uncoupled” from its adverse metabolic effects (26). Our MR analyses infer that higher 
WHR (adjusted for BMI) elevates ACR. In contrast, having more favourable adiposity alleles 
lowers ACR. The favourable adiposity variants are known to associate with higher 
subcutaneous fat, but lower liver fat and lower visceral-to-subcutaneous adipose tissue ratio 
(26).  This provides further evidence that body fat distribution may be important in albuminuria 
and microvascular problems. Previous studies have suggested a role for body fat distribution 
and visceral fat in albuminuria, although to date, these studies have had low numbers of 
participants and have only used observational data so are subject to more biases than the 
genetic approach employed in this study (10; 36; 37). A consistent trend was also noted for BMI, 
with higher BMI trending towards elevated ACR. These results suggest that adiposity and 
distribution of fat are important in elevating ACR and suggests a causal role for adiposity and fat 
distribution in microvascular dysfunction.  
Our analyses strengthen previous work demonstrating that higher systolic and diastolic blood 
pressure cause albuminuria (13). Our results confirmed the direction and magnitude of the MR 
inferred causal role of systolic and diastolic blood pressure on ACR recently reported (13) and 
support evidence from clinical trials showing that anti-hypertensive treatments acting on the 
Renin-angiotensin system reduce ACR (38).  
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As expected, our MR results confirm that diabetes plays a major role in raising ACR levels.  
These results add genetic evidence to the large body of data from observational studies and 
clinical trials clearly showing the role of T2D in causing renal damage. There was no genetic 
evidence for fasting insulin or fasting glucose levels causing elevated ACR levels. This is in 
contrast with observational studies showing an association between fasting insulin or fasting 
glucose and ACR levels (39; 40). This may indicate that these observational associations are 
driven by confounding factors.  
The major strength of this study is the availability of data in the UK Biobank and a large 
independent GWAS sample for testing the causal relationships using 2-sample MR approaches. 
Another strength is the use of multiple rigorous MR methods to establish causality in this 
analysis. MR provides the next best evidence of causality after randomized control trials and 
allow causal inferences on large scale databases such as those used in study. 
We acknowledge, however, some limitations. Firstly, Mendelian randomization studies are not 
immune from some of the issues that affect observational studies. For example, it is possible 
that biases such as survival bias could have affected the MR as well as observational studies. If, 
for example, a high ACR and high LDL-cholesterol level results in a high mortality rate due to 
microvascular disease (e.g. stroke), then genetic factors that raise LDL-Cholesterol level could 
be depleted from the study and associations between LDL-cholesterol raising alleles and ACR 
could be weakened. This type of bias has been pointed out before (41). Secondly, our analyses 
were restricted to individuals of Caucasian descent and the UK Biobank is restricted to 
participants born between 1938 and 1971, therefore the generalisability of our findings may be 
limited. Thirdly, although multivariate MR was utilised to explore the role of the three lipids on 
ACR, there remains the potential for some residual bias due to the pleiotropic associations of 
the lipid variants, although more pleiotropy resistant methods generally provided consistent 
results. Finally, some of our instrumental variables explain only a small percentage of the 
variability of the outcome variable and therefore we might be underpowered to detect causal 
association in some of the analysis. 
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In conclusion, we have utilised a genetic approach to show the causal role of 7 metabolic risk 
factors on ACR and provided evidence that dyslipidemia, adiposity and distribution of adipose 
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Table 1. Participants’ characteristics. Data are presented as mean (±standard deviation) 
and median [25th -75th percentile] where not otherwise stated. 
 
  UK Biobank SUMMIT 
N 438,075 743 
Age (yrs) 57.27 (± 8.02) 66.16 (± 8.82) 
Sex [N males (%)] 237,181 (54.14%) 480 (64.60%) 
Height (cm) 168.7 (± 9.2) 169.6 (± 0.09) 
BMI 27.38 (± 4.75) 29.55 (± 5.22) 
ACR (mg/mml) 1.10 [0.69 - 1.85] 0.70 [0.45 - 1.4] 
CAD [N (%)] 36,434 (10.53%) 223 (30.01%) 
T2D [N (%)] 13,799 (3.21%) 400 (53.84%) 
Systolic BP (mmHg) 144.2 (± 24.0) 136.7 (16.5) 
Diastolic BP (mmHg) 86.3 (± 13.5) 76.9 (8.71) 
 
BMI = body mass index, ACR = albumin creatinine ratio, CAD = coronary arterial disease, 





Table 2. UK Biobank observational association results between investigated traits and ACR for 
observational data.  
 
Trait UK Biobank Beta* UK Biobank SE UK Biobank P 
Diastolic BP 0.113 0.001 < 1.0E-15 
Systolic BP 0.155 0.002 < 1.0E-15 
HDL cholesterol 0.068 0.002 < 1.0E-15 
LDL cholesterol -0.018 0.002 < 1.0E-15 
Triglycerides -0.047 0.002 < 1.0E-15 
BMI -0.106 0.001 < 1.0E-15 
% Body fat -0.116 0.002 < 1.0E-15 
Waist hip ratio (adjusted by BMI) 0.008 0.002 4.30E-07 
Fasting glucose Not available Not available Not available 
Fasting insulin Not available Not available Not available 
T2D 0.353 0.008 < 1.0E-15 
 
*Beta represents the standard deviation change in ACR per unit standard deviation change in 
continuous traits or change based on case-control status for binary traits. SE = standard error.  
BP = blood pressure, BMI = body mass index, T2D = type 2 diabetes, BP = blood pressure. 
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Table 3. ACR results of meta analysis of Mendelian randomization results in UK Biobank and 
CKDGen. Betas represent standard deviation change in ACR for standard deviation change in 
metabolic trait, 95% confidence interval in brackets.  
        Main MR analysis  Pleiotropy robust methods 
Trait Beta IVW P IVW Beta Egger P Egger Beta WM P WM Beta PWM P PWM 
Diastolic BP 0.009 (0.006, 0.012) 2.0E-09 -0.001 (-0.009, 0.008) 8.3E-01 0.009 (0.006, 0.012) 6.8E-10 0.008 (0.004, 0.011) 1.0E-05 
Systolic BP 0.006 (0.004, 0.008) 3.8E-08 0.001 (-0.005, 0.007) 7.6E-01 0.006 (0.004, 0.007) 2.9E-09 0.005 (0.003, 0.008) 1.8E-06 
HDL cholesterol -0.012 (-0.029, 0.006) 1.9E-01 0.012 (-0.013, 0.036) 3.5E-01 0.014 (-0.002, 0.030) 7.7E-01 0.014 (-0.009, 0.037) 2.5E-01 
LDL cholesterol 0.026 (0.008, 0.044) 5.0E-03 0.022 (-0.006, 0.049) 1.2E-01 0.030 (0.014, 0.047) 2.6E-04 0.027 (0.009, 0.045) 3.8E-03 
Triglycerides 0.062 (0.040, 0.083) 1.3E-08 0.064 (0.033, 0.096) 5.6E-05 0.050 (0.030, 0.070) 7.8E-07 0.054 (0.026, 0.082) 1.3E-04 
BMI 0.024 (-0.002, 0.050) 7.3E-02 0.088 (0.031, 0.144) 2.3E-03 0.015 (-0.015, 0.045) 3.2E-01 0.033 (-0.002, 0.068) 6.1E-02 
Favourable 
adiposity* -0.157 (-0.256, -0.057) 1.9E-03 0.082 (-0.017, 0.334) 5.2E-01 -0.143 (-0.230, -0.560) 1.3E-03 -0.143 (-0.266, -0.021) 2.1E-02 
Waist hip ratio 
(adjusted by BMI) 0.040 (0.020, 0.059) 6.3E-05 0.099 (0.051, 0.146) 4.9E-05 0.050 (0.027, 0.073) 2.0E-05 0.032 (0.008, 0.056) 8.0E-03 
Fasting glucose -0.014 (-0.073, 0.044) 6.3E-01 -0.039 (-0.152, 0.074) 5.0E-01 -0.017 (-0.062, 0.028) 4.5E-01 -0.016 (-0.064, 0.032) 5.0E-01 
Fasting insulin -0.018 (-0.215, 0.179) 8.6E-01 -1.318 (-2.409, -0.227) 1.8E-02 -0.035 (-0.159, 0.089) 5.8E-01 -0.032 (-0.170, 0.106) 6.5E-01 
T2D liability 0.013 (0.006, 0.021) 5.2E-04 0.021 (0.006, 0.036) 7.6E-03 0.021 (0.012, 0.031) 1.4E-05 0.023 (0.011, 0.034) 1.1E-04 
IVW = inverse variance weighted instrumental variable analysis, WM = weighted median 
analysis, PWM = penalised weighted median analysis. 
BP = blood pressure, BMI = body mass index, T2D = type 2 diabetes. 
*Favourable adiposity - represents higher adiposity but lower metabolic disease risk using 
genetic variants identified in Ji et al (26). 
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When removing SNPs associated with ACR at genome wide significance the results were 
consistent with the previous results [Diastolic BP: Beta IVW = 0.069 (-0.050, 0.188), p = 7.5E-
10; HDL cholesterol: Beta IVW = 0.069 (-0.050, 0.188), p = 4.1E-02; Triglycerides: Beta IVW = 
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